Related by context. All words. (Click for frequent words.) 70 lexidronam injection 70 antibody MAb 69 INGN 69 orally administered inhibitor 68 preclinical efficacy 68 telaprevir VX 68 IgG1 monoclonal antibody 68 MEK inhibitor 68 investigational humanized monoclonal antibody 68 YONDELIS 68 PSMA ADC 68 liposomal formulation 68 AEG# 67 AEGR 67 mertansine 67 Azedra 67 IAP inhibitors 67 MAGE A3 ASCI 67 Bezielle 67 Onconase 67 histone deacetylase HDAC inhibitor 67 PRTX 67 samarium Sm 67 histone deacetylase inhibitor 67 PARP inhibitor 67 MEK Inhibitor 67 AAG geldanamycin analog 67 Apaziquone 67 thymalfasin 67 huC# DM4 67 MAGE A3 66 PDE4 inhibitor 66 targeted radiotherapeutic 66 targeting CD# 66 IgG1 antibody 66 depsipeptide 66 FOLOTYN ® 66 AQ4N 66 GLPG# 66 oral prodrug 66 DPX Survivac 66 pan HDAC inhibitor 66 MT# MEDI 66 immunotherapeutic vaccine 66 chimeric monoclonal antibody 66 Cloretazine ® 66 HCV protease inhibitors 66 HDAC Inhibitor 66 Virulizin ® 66 neratinib 66 CR# vcMMAE 66 rhFVIIa 66 TRX1 65 alvespimycin 65 darinaparsin ZIO 65 INSPIRE Trial Phase III 65 LY# [002] 65 Hsp# Inhibitor 65 Allovectin 7 R 65 orally bioavailable 65 INCB# [001] 65 forodesine 65 oral Hsp# inhibitor 65 Tarvacin TM 65 Afatinib 65 non nucleoside inhibitor 65 VQD 65 Ixempra 65 elotuzumab 65 Debio 65 Multimeric 65 EndoTAG TM 65 RELOVAIR ™ 65 UPLYSO 65 Archexin 65 huN# DM1 65 Phase Ib clinical trials 65 YONDELIS R 65 PHX# 65 Phase Ib II 65 ATL# [001] 65 PSN# [002] 65 sorafenib tablets 65 Civacir 65 KSP inhibitor 65 proteasome inhibitor 65 bortezomib Velcade 65 humanised monoclonal antibody 65 Irinotecan 65 TKM ApoB 65 Cethromycin 65 PXD# 65 A3 adenosine receptor 65 AEZS 65 Varespladib 65 PROSTASCINT R 65 DermaVir Patch 65 CD# antibody [001] 65 JAK inhibitor 65 μg dose 65 MGd 65 IMA# 65 phase IIb trial 65 Peginterferon alfa 2b 65 mitogen activated ERK kinase 65 Amrubicin 65 Aplidin 65 PDX pralatrexate 65 CINTREDEKIN BESUDOTOX 65 Kahalalide F 65 trastuzumab Herceptin R 65 CCX# 65 HuMax EGFr 64 HCV protease inhibitor 64 rxRNA 64 Phase #b/#a clinical 64 JVRS 64 Panzem R 64 Golimumab 64 pain palliation 64 Phase 2b Clinical Trial 64 Onalta ™ 64 SNT MC# 64 farletuzumab 64 PI3K/Akt pathway inhibitor 64 Tanespimycin 64 isoform selective 64 ELACYT 64 Lenocta 64 humanized monoclonal antibody 64 CRx 64 tubulin inhibitor 64 CIMZIA TM 64 CIMZIA ™ 64 lintuzumab SGN 64 TRO# 64 enzastaurin 64 volociximab 64 vinca alkaloid 64 IL# PE#QQR 64 Traficet EN 64 tanespimycin 64 ThermoDox R 64 AKT inhibitor 64 CTAP# Capsules 64 IAP inhibitor 64 IMC #B 64 liposomal doxorubicin 64 LUX Lung 64 Myocet 64 non nucleoside 64 oral ridaforolimus 64 Panzem 64 prasugrel CS 64 Drug Candidate 64 SUVN 64 novel histone deacetylase 64 Trofex 64 PEG SN# 64 Sym# 64 ENMD # 64 humanized anti 64 cathepsin K inhibitor 64 CCR5 antagonist 64 CCR9 64 Diamyd ® 64 Genasense ® 64 Alocrest 64 humanized monoclonal 64 RGB # 64 vascular disrupting agents 64 hA# 64 Trastuzumab DM1 64 CoFactor 64 EOquin TM 64 ARRY # 64 HER2 positive metastatic breast 64 RG# ITMN 64 Pertuzumab 64 poly ADP ribose polymerase 64 HGS ETR2 64 Triapine 64 Insegia 64 Ocrelizumab 64 EZN 64 cyclophilin inhibitor 64 anti EGFR antibody 64 Factor VIIa 64 Nanobody 64 CEQ# 64 lymphoid malignancies 64 Aflibercept 63 erlotinib Tarceva ® 63 Initiates Phase II 63 Phase IIb Clinical Trial 63 trastuzumab DM1 63 phase Ib 63 BRAF inhibitor 63 docetaxel Taxotere R 63 Phase IIb clinical trials 63 Tesmilifene 63 inhibitor RG# 63 humanised antibody 63 Allovectin 7 ® 63 Dapagliflozin 63 IMiDs ® 63 milatuzumab 63 drug conjugate 63 targeted antifolate 63 anti PlGF 63 GW# [003] 63 Solazed 63 Telatinib 63 Pivotal Phase III 63 monoclonal anti 63 pitavastatin 63 OMP #M# 63 pomalidomide 63 JAK2 inhibitor 63 Cetrorelix 63 NOX E# 63 TMC# [002] 63 Carfilzomib 63 Phase 2a trial 63 Vicinium TM 63 CD# CEA 63 Allovectin 7 63 HZT 63 trabectedin 63 HQK 63 Anticalin R 63 Nexavar ® 63 multi kinase inhibitor 63 Virulizin R 63 investigational compound 63 novel VDA molecule 63 JAK inhibitors 63 Onalta 63 immatics 63 Aviptadil 63 gefitinib Iressa 63 NeuVax 63 HSP# inhibitor 63 PNP inhibitor 63 Pradefovir 63 OMP #R# 63 Xanafide 63 Monoclonal Antibody 63 anticancer compound 63 IIa trial 63 IMiDs ® compound 63 PLK1 SNALP 63 IMC A# 63 cannabinor 63 Potelligent Technology 63 R#/MEM # 63 incyclinide 63 thalidomide Thalomid 63 sunitinib malate 63 oral picoplatin 63 amrubicin 63 Eribulin 63 HGS# 63 demonstrated antitumor activity 63 bendamustine 63 therapeutic monoclonal antibody 63 talactoferrin 63 QUADRAMET R 63 Phase Ib study 63 Phase Ib clinical 63 RNAi therapeutic targeting PCSK9 63 adecatumumab MT# 63 favorable pharmacokinetic profile 63 Cytochrome P# 63 MKC# MT 63 radiolabeled 63 Cloretazine 63 Vitaxin 63 Aplidin R 63 interferon gamma 1b 63 SAR# [004] 63 IMGN# 63 refractory CLL 63 anti CD3 63 human IgG1 monoclonal 63 standard chemotherapy regimen 63 Oral NKTR 63 HepaSphere 63 HCV protease 63 reslizumab 63 davunetide intranasal AL 63 vitro cytotoxicity 63 GLP toxicology studies 63 Daclizumab 63 Velcade bortezomib 63 AzaSite Plus 63 Presents Preclinical Data 63 lorvotuzumab mertansine 63 XL# XL# 63 LHRH antagonist 63 Poly ICLC 63 Initiate Phase 63 Phase IIa trial 63 Initiate Clinical Trial 63 receptor tyrosine kinase inhibitor 63 Abiraterone acetate 62 Anticalins ® 62 MKC# MKC# PP 62 ZACTIMA 62 Kamada AAT 62 epothilones 62 IMiDs R 62 treatment naïve genotype 62 DPP4 62 FRDA 62 Guanilib 62 Omacetaxine 62 investigational therapies 62 K ras mutations 62 Exherin TM 62 Vidaza azacitidine 62 ceftazidime 62 HGS ETR1 62 rhMBL 62 polymerase inhibitor 62 Vandetanib 62 monoclonal antibody conjugated 62 selective modulator 62 systemic RNAi therapeutic 62 humanized antibody 62 solithromycin 62 MEK inhibitors 62 preclinically 62 vidofludimus 62 REGN# 62 PEG Interferon lambda 62 sorafenib Nexavar 62 Parathyroid Hormone 62 Icatibant 62 HIV integrase inhibitor 62 immunotoxin 62 PKC# 62 cilengitide 62 Seliciclib 62 potent antiproliferative 62 multicenter Phase II 62 EpCAM 62 Pharmacokinetics PK 62 multiple myeloma MM 62 Proellex TM 62 RhuDex R 62 ZK EPO 62 Phase III Clinical Trial 62 EndoTAG 62 Phase IIIb clinical 62 Meets Primary Endpoint 62 PrevOnco 62 ALN HPN 62 BAY #-# 62 Factor Receptor 62 phase IIb clinical 62 selective androgen receptor modulators 62 BioNumerik 62 phase IIa clinical 62 ospemifene 62 JAK3 62 CD3 monoclonal antibody 62 EndoTAG TM -1 62 RAV# 62 BRIM3 62 Perifosine 62 immunoconjugate 62 virus HCV protease inhibitor 62 urocortin 2 62 radiolabeled TM# 62 #D#C# 62 cMET 62 Aurora kinase inhibitor 62 CCR9 antagonist 62 fosbretabulin 62 FGFR 62 personalized immunotherapy 62 EGEN 62 HyperAcute 62 CDK inhibitor 62 tremelimumab 62 R sorafenib tablets 62 refractory chronic lymphocytic 62 TPI ASM8 62 Mipomersen 62 trastuzumab emtansine T DM1 62 telomerase therapeutic 62 Enzastaurin 62 tolerability pharmacokinetics 62 indibulin 62 Hedgehog antagonist 62 Campath ® 62 OvaRex R 62 mTOR mammalian target 62 RNAi therapeutic targeting 62 Zybrestat 62 lexidronam injection PROSTASCINT 62 nucleoside analog 62 Safinamide 62 TG# [003] 62 Ceflatonin 62 novel immunomodulatory 62 ALN TTR 62 octreotide implant 62 Aryplase 62 PREOS R 62 Cancidas 62 CXA 62 Firazyr 62 BrachySil TM 62 HuMax CD4 62 CanAg 62 HER2 antibody 62 TLR9 agonist 62 TLR9 agonists 62 mda 7 62 ADXS# 62 Tarceva TM 62 PRT# 62 Oritavancin 62 Successfully Completes Phase 62 torezolid phosphate 62 Completes Patient Enrollment 62 JAK1 62 relapsed refractory multiple myeloma 62 oral FTY# 62 ZOLINZA 62 Exelixis XL# 62 DNA intercalator 62 Aurora kinase 62 pegylated liposomal doxorubicin 62 hyaluronidase enzyme 62 ATL# [002] 62 Personalized Immunotherapy 62 ARRY 62 TKB# 62 HuMax TAC 62 prucalopride 62 HuLuc# 62 deforolimus 62 Pemetrexed 62 Breast Cancer Assay 62 CYT# potent vascular disrupting 62 Phase 2a Clinical Trial 62 sodium glucose cotransporter 62 Rebif ® 62 Tyrima 62 Vascular Disrupting Agent 62 Belinostat 62 HCV replicon 62 ALN PCS 62 anticancer activity 62 pharmacodynamic PD 62 CRLX# 62 novel synthetic PEGylated 62 Receives Orphan Drug Designation 62 Cerashield 62 TGR5 62 Phase 1b clinical trials 62 BCIRG 61 Granted Orphan Drug 61 CUDC 61 Phase IIa trials 61 orally dosed 61 axitinib 61 Panzem R NCD 61 cetuximab Erbitux R 61 Preclinical studies suggest 61 Multiple Ascending Dose 61 Tezampanel 61 Solid Tumors 61 Angiolix 61 radiation sensitizer 61 metastatic hormone refractory 61 Hycamtin 61 G#DT 61 optimal dosing 61 iobenguane 61 RhuDex ® 61 Pathway Inhibitor 61 MT#/MEDI-# 61 Erbitux cetuximab 61 novel anticancer 61 intranasal formulation 61 radiolabeled monoclonal antibody 61 ONCONASE 61 hypoxia activated prodrug 61 Tamibarotene 61 nucleotide analog 61 Pafuramidine 61 MCSP respectively 61 peptidic compound 61 Talactoferrin 61 PEGylated Fab fragment 61 Phenoptin 61 Davanat 61 EOquin 61 Inhalation Solution 61 Zolinza 61 OvaRex ® MAb 61 JAK Inhibitor 61 Systemic Delivery 61 Atrasentan 61 lumiliximab 61 Pimavanserin 61 GVAX ® 61 acyclovir Lauriad R 61 Zalypsis 61 torezolid 61 Ecallantide 61 velafermin belinostat 61 optimal dosing regimens 61 Squalamine 61 Immunotherapeutic 61 Nexavar sorafenib 61 tranilast 61 gemcitabine carboplatin 61 Presents Preclinical 61 posaconazole 61 Sapacitabine 61 compound ITMN 61 highly selective inhibitor 61 anticoagulant reversing agent 61 immune modulatory 61 midstage trials 61 KRN# 61 cytochrome P 61 Preclinical Study 61 Liposomal 61 GAP #B# 61 initiate Phase 1b 61 thetreatment 61 Darinaparsin 61 clinical pharmacology studies 61 metaglidasen 61 Elesclomol 61 Ozarelix 61 Capesaris 61 dexpramipexole 61 trastuzumab DM1 T DM1 61 budesonide foam 61 MEK inhibitor ARRY 61 Degarelix 61 AP# [003] 61 investigational pan BCR 61 TEMODAL 61 mapatumumab 61 HDAC inhibitor 61 CytoFabTM 61 investigational protease inhibitor 61 pertuzumab 61 cleavable linker 61 OncoVEX 61 Peginterferon 61 obatoclax 61 EGFR HER2 61 Panitumumab 61 pharmacodynamic markers 61 CD4 monoclonal antibody 61 microtubule inhibitor 61 CD# expressing 61 tipifarnib 61 pathophysiological effects 61 rALLy clinical trial 61 miRview mets 61 uricase 61 Troxatyl 61 Cannabinor 61 Kinase Inhibitor 61 docetaxel Taxotere ® 61 Initiates Phase 61 MAGE A3 protein 61 Tarvacin 61 novel oral anticoagulant 61 CINOD 61 fluoropyrimidine 61 Actimmune ® 61 NCCTG 61 Panzem NCD 61 CCR5 mAb 61 REP# 61 bardoxolone 61 Ambrisentan 61 Randomized Phase 61 Xcytrin R 61 MGCD# [001] 61 antisense drug 61 Removab 61 selective kinase inhibitor 61 Vidofludimus 61 Nanobody ® 61 metastatic colorectal 61 Neulasta R 61 REMUNE R 61 IND submission 61 ganetespib 61 prostone 61 Bortezomib 61 chemically modified siRNA 61 Enzyme Replacement Therapy 61 atrasentan 61 MyVax R 61 HuMax CD# 61 registrational trial 61 ORMD 61 BZL# 61 Vernakalant 61 regorafenib 61 GLYX 61 Epratuzumab 61 delta isoform 61 PD LID 61 mGluR2 NAM 61 anti CD# antibodies 61 StemEx 61 P#X# antagonist 61 selective S#P# receptor agonist 61 investigational compounds 61 diarrhea predominant irritable 61 SIR Spheres 61 Prodarsan R 61 COU AA 61 evaluating satraplatin 61 systemically administered 61 CCR1 61 DPP4 inhibitor 61 bevacizumab Avastin ® 61 TBC# 61 metastatic RCC 61 Alpharadin 61 IIb clinical trial 61 elvucitabine 61 Posiphen 61 Gefitinib 61 evaluating tivozanib 61 LEP ETU 61 Yondelis ® 61 peripherally acting 61 immunomodulatory properties 61 IMiD 61 Initiates Clinical 61 successfully commercialize Iluvien 61 Tykerb lapatinib 61 synthetic retinoid 61 p# biomarker 61 Initiates Clinical Trial 61 Biomarker Study 61 pharmacodynamic properties 61 Reports Preclinical Data 61 Raptiva ® 61 2 inhibitor CYT# 61 NEUPOGEN R 61 cinacalcet 61 peptibody 61 selective androgen receptor modulator 61 dasatinib Sprycel 61 hypoxia inducible factor 61 perampanel 61 HCV NS5B polymerase 61 MAb 60 Campath alemtuzumab 60 NPC 1C 60 PEG PAL 60 SinuNase ™ 60 motesanib diphosphate 60 EndoTAGTM 1 60 hyperphenylalaninemia HPA due 60 Iloperidone 60 Commences Phase 60 registrational 60 ISTODAX 60 R roscovitine 60 TASKi2 60 Neupogen ® 60 DCCR 60 GTC recombinant human 60 oral ghrelin agonist 60 HuMax HepC TM 60 plus prednisone 60 HuMax 60 afatinib 60 recurrent NSCLC 60 GMX# 60 DiLA2 60 brivanib 60 Phase Ib Clinical Trial 60 plasma kallikrein inhibitor 60 hoFH 60 PrevOnco ™ 60 DEB# 60 ALN TTR# 60 MTP inhibitor 60 ONCONASE R 60 IRX 2 60 TELINTRA 60 HoFH 60 Phase IIb trials 60 CBLC# 60 nonclinical studies 60 Pivotal Study 60 radiotherapeutic 60 entinostat 60 Forodesine HCl 60 eprotirome 60 lead Aganocide compound 60 Intravenous Human 60 ruxolitinib 60 PCK# 60 antitumoral 60 Maribavir 60 aurora kinase inhibitor 60 SNT-MC#/idebenone 60 Initiates Phase III 60 Pazopanib 60 humanized monoclonal antibodies 60 plasma pharmacokinetics 60 TKM PLK1 60 SCH # 60 DAVANAT 60 neuroprotective properties 60 ELND# AZD 60 oral deforolimus 60 FLT3 60 AGS PSCA 60 Litx 60 luliconazole 60 HCD# [002] 60 Silodosin 60 Anticalins R 60 aflibercept 60 Granulocyte Colony Stimulating Factor 60 IPL# 60 photoprotective drug 60 radezolid 60 cyclophilin inhibitors 60 TG MV 60 small molecule tyrosine 60 Quinamed 60 AVONEX ® 60 Collategene 60 OHR/AVR# 60 multikinase inhibitor 60 specific lectin receptors 60 Ceflatonin R 60 DU #b 60 xenograft models 60 selective orally bioavailable 60 Aurora Kinase 60 CYC# 60 zanolimumab 60 anti amnesic 60 immuno modulatory 60 Valortim R 60 Alfacell proprietary ribonuclease 60 HCV polymerase 60 reversible inhibitor 60 Phase Ib 60 induced macular edema 60 HDACi 60 Bruton tyrosine kinase Btk 60 resolvin 60 XL# anticancer compounds 60 acetonide FA 60 Phase 1a clinical 60 beta 1a 60 oral antiviral 60 adecatumumab 60 LymphoStat B TM 60 alemtuzumab Campath 60 immunotoxins 60 ALN VSP 60 cinacalcet HCl 60 Chemokine Receptor 60 relapsing multiple sclerosis 60 Friedreich Ataxia FRDA 60 Romidepsin 60 dasatinib Sprycel ® 60 Bavituximab 60 histone deacetylase HDAC 60 Imprime PGG 60 LBH# 60 miRview TM mets 60 compound INCB# 60 SAR# [002] 60 trastuzumab Herceptin ® 60 NTDDS 60 Loramyc R 60 molecular imaging radiopharmaceutical 60 Omacetaxine mepesuccinate 60 non nucleoside HCV 60 PF # [001] 60 Proxinium TM 60 maribavir 60 novel peptide 60 Aclidinium 60 Orphan Drug status 60 Eluting Stent 60 Adnectin 60 Sphingosine 1 60 treatment naive genotype 60 Spiegelmer ® 60 Syncria 60 viral kinetics 60 polymerase inhibitors 60 eniluracil 60 polysaccharide polymer 60 castrate resistant prostate cancer 60 antibody MT# 60 anti secretory 60 topically applied SEPA 60 antisense inhibitor 60 Palifosfamide 60 rilonacept 60 recombinant biopharmaceutical 60 Elvitegravir 60 ADP receptor antagonist 60 Sphingomab 60 Novel Small Molecule 60 Mimpara 60 sarcoma melanoma 60 CALGB 60 chemoresistant 60 multicenter Phase III 60 eritoran 60 dihydrochloride 60 VitiGam 60 omega interferon 60 methylnaltrexone bromide 60 iniparib BSI 60 StemEx R 60 AFFiRiS 60 dose escalation clinical 60 selective agonist 60 MGN# 60 BRAF V# mutation 60 TG# [001] 60 Thiarabine 60 fostamatinib 60 refractory metastatic 60 efaproxiral 60 Aliskiren 60 INCB# [003] 60 RNA antagonist 60 NXL# 60 SUTENT ® 60 Onalta TM 60 Azacitidine 60 panitumumab Vectibix 60 antisense inhibitors 60 CERE 60 MVA BN 60 recurrent metastatic 60 BLA submission 60 Recombinant Human 60 NeuroSTAT ® 60 HCV SPRINT 60 Microplasmin 60 Thiovir 60 epigenetic therapies 60 HER1 60 Kissei Pharmaceutical 60 estramustine 60 HDL Selective Delipidation 60 OncoVEX GM CSF 60 Prostate AdenoCarcinoma Treatment 60 Antiangiogenic 60 immunotherapeutic agent 60 Adenuric R 60 CLL8 60 ularitide 60 TheraCIM 60 synthetic peptide 60 GRNVAC1 60 intravesical instillation 60 leading oral taxane 60 Temsirolimus 60 metastatic renal cell carcinoma 60 PSN# [001] 60 Initiates Phase 2b 60 Oracea TM 60 effector function 60 BENLYSTA ® 60 EFAPROXYN 60 Dalbavancin 60 tiapamil 60 pharmacological chaperone 60 Advanced Renal Cell 60 investigational monoclonal antibody 60 Tavocept 60 BGC# 60 Tarmogen 60 potent anticancer 60 Xyfid TM 60 varespladib 60 Inhaled AAT 60 MOVIPREP R 60 sunitinib Sutent 60 Clavis Pharma 60 riociguat 60 vivo potency 60 antitumor effect 60 ARIKACE ™ 60 Preclinical studies 60 TroVax ® 60 Neuvenge 60 pharmacokinetic PK study 60 NP2 Enkephalin 60 Angiocept 60 Phase 1b clinical 60 Initiates Enrollment 60 mg q#h 60 VEGF Trap 60 HepDirect prodrug 60 PORxin TM 60 Achieves Primary Endpoint 60 Canvaxin TM 60 Cethrin R 60 T#I [002] 60 GSK# [001] 60 VNP#M 60 acid phosphatase PAP 60 haematologic malignancies 60 CANCIDAS 60 Anticancer Compound 60 essential thrombocythemia ET 60 RhuDex TM 60 immune modulating 60 eribulin mesylate 60 Pirfenidone 60 adalimumab Humira 60 satraplatin Phase 60 M2 subunit 60 Receives Orphan Drug 60 selective immunoproteasome inhibitor 60 selective adenosine 60 Calcitonin 60 Hsp# inhibition 60 PROCHYMAL 60 lintuzumab 60 Certican 60 Janus Kinase 60 Azedra ™ 60 ISIS # 60 Kit CD# positive 60 GTC recombinant form 60 dutogliptin 60 galiximab 60 PDE# inhibitors 60 Protexia R 60 cell lymphoma CTCL 60 oncolytic vaccine 60 BRIM2 60 CCR2 60 Teysuno 60 ErbB3 60 p# inhibitor 60 Exelixis compounds 60 NS#/#A protease 60 pediatric acute lymphoblastic 60 Interferon alfa 60 Mg Usa 60 biologic therapeutics 60 Tesetaxel 60 Gleevec resistant 60 Ophena TM 60 tkRNAi 60 OMNARIS HFA 60 Phase 2a clinical 60 Triolex 60 Onrigin 59 Trandolapril 59 intratumoral injection 59 BiTE 59 pharmacokinetic parameters 59 protein kinase inhibitor 59 PS# [001] 59 Vaxfectin 59 XL# XL# XL# XL# 59 intranasal delivery 59 PGL# 59 Cethrin 59 flavopiridol 59 Symadex 59 Phase #b/#a 59 Fibrillex TM 59 Anti Tumor 59 assay detects 59 murine monoclonal antibody 59 Curaxin 59 LymphoStat B belimumab 59 Urocidin 59 MET amplification 59 PKCi 59 novel oral tubulin